ProHance MRI Contrast Lawyers No Longer Reviewing New Cases
Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy (NSF/NFD) has been linked to ProHance side effects.
ProHance (gadoteridol) is an injection placed into the vein before an MRI or MRA exam to provide contrast on the test results so the radiologist can easily identify blood vessels.
The injection contains gadolinium, and is one of five MRI contrast agents which could lead to a serious and potentially fatal disorder for those with impaired renal function.
ProHance was approved by the FDA in 1999. It is manufactured by Bracco Diagnostic, Inc., which also makes a newer gadolinium-based contrast which was approved in 2004, MultiHance. All gadolinium contrasts have been associated with a risk of NFD/NSF for those with kidney disease.
ProHance lawsuits were previously reviewed by the lawyers at Saiontz & Kirk, P.A. for individuals with kidney problems who were diagnosed with Nephrogenic Fibrosing Dermopathy, or Nephrogenic Systemic Fibrosis, after receiving an MRI contrast injection. New cases are no longer being accepted or pursued.
Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis are both used to describe the same disorder, which involves the formation of thick and tight skin on the extremities and sometimes the trunk. It can also lead to fibrosis of internal organs, limitations on mobility and even death. The disease is progressive and there is no effective treatment available.
Signs of ProHance side effects which could be symptoms of NFD/NSF include:
- Thickened, tight, rigid and coarse skin
- Red or dark patches
- Burning or itching sensation
- Deep pain in the hip or ribs
- General weakness of the muscles
>>INFORMATION: Gadolinium Side Effects
The attorneys at Saiontz & Kirk, P.A. are no longer investigating potential gadolinium law suits for individuals with impaired kidney function who suffered from NFD/NSF. ProHance is one of five gadolinium contrasts associated with the development of the condition. The others include: